US 2022/0033460 A1 · IDENTIFICATION AND USE OF T CELL EPITOPES IN DESIGNING DIAGNOSTIC AND THERAPEUTIC APPROACHES FOR COVID-19

Abstract

Approaches for identifying T cell epitopes from SARS-CoV-2 are provided, along with the use of such T cell epitopes diagnostically and therapeutically. Compositions including T cell epitope vaccines and T cell epitope-display reagents are provided. Methods for identifying SARS-CoV-2 T cell epitopes, methods of identifying reactive T cells and methods of using epitopes and T cells for diagnostic purposes, such as identifying particular patient subpopulations are provided. Treatment methods, including administration of T cell epitope vaccines prophylactically and administration of activated T cells therapeutically are also provided.

Claims46

Dependent claims

An isolated peptide comprising an immunodominant SARS-CoV-2 T cell epitope comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:

286, 288, 324, 326, 327, and 328, wherein the peptide is no more than 100 amino acids in length, and an optional pharmaceutically acceptable carrier.

A pharmaceutical composition comprising an engineered T cell and a pharmaceutically acceptable carrier, wherein the engineered T cell comprises one or more exogenous nucleic acid sequences that encode a TCR having antigenic specificity for a SARS-CoV-2 antigen, the TCR have an alpha chain and a beta chain, wherein:

(a) the SARS-CoV-2 antigen comprises a T cell epitope comprising the amino acid sequence of SEQ ID NO:
286 presented by HLA-A*02:01, and the TCR comprises the CDR3 alpha and CDR3 beta sequences of TCR_22, TCR_27, TCR_47, TCR_65, TCR_69, TCR_77, TCR_84, or TCR_107 set forth in Table 5;
(b) the SARS-CoV-2 antigen comprises a T cell epitope comprising the amino acid sequence of SEQ ID NO:
288 presented by HLA-A*02:01, and the TCR comprises the CDR3 alpha and CDR3 beta sequences of TCR_5, TCR_7, TCR_14, TCR_16, TCR_20, TCR_28, TCR_33, TCR_43, TCR_45, TCR_63, TCR_70, TCR_81, TCR_86, TCR_88, TCR_90, TCR_94, TCR_98, TCR_99, TCR_102, TCR_103, TCR_106, TCR_108, TCR_113, or TCR_123 set forth in Table 5;
(c) the SARS-CoV-2 antigen comprises a T cell epitope comprising the amino acid sequence of SEQ ID NO:
324 presented by HLA-B*07:02, and the TCR comprises the CDR3 alpha and CDR3 beta sequences of TCR_16, TCR_22, TCR_27, TCR_65, TCR_97, or TCR_107 set forth in Table 5;
(d) the SARS-CoV-2 antigen comprises a T cell epitope comprising the amino acid sequence of SEQ ID NO:
326 presented by HLA-B*07:02, and the TCR comprises the CDR3 alpha and CDR3 beta sequences of TCR_11, TCR_112, or TCR_122, set forth in Table 5;
(e) the SARS-CoV-2 antigen comprises a T cell epitope comprising the amino acid sequence of SEQ ID NO:
327 presented by HLA-A*01:01, and the TCR comprises the CDR3 alpha and CDR3 beta sequences of TCR_26, TCR_53, or TCR_54 set forth in Table 5;
or
(f) the SARS-CoV-2 antigen comprises a T cell epitope comprising the amino acid sequence of SEQ ID NO:
328 presented by HLA-A*01:01, and the TCR comprises the CDR3 alpha and CDR3 beta sequences of TCR_25 or TCR_41 set forth in Table 5.

10 more elements

Dependencies are inferred from the claim text.

Identification and use of t cell epitopes in designing diagnostic and therapeutic approaches for covid-19

Life of this patent

Identification and use of t cell epitopes in designing diagnostic and therapeutic approaches for covid-19

Life of this patent

Abstract

Claims46